MiMedx Group Inc (MDXG)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at MiMedx Group Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Basics
Performance
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 61.0% above the current price.
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 0.05 | -86.20 | 93 | 7.00 | 8.00 | 19 | 19 |
| 2025: Q1 | 0.05 | -24.00 | 88 | 4.10 | 8.00 | 5 | 5 |
| 2025: Q2 | 0.06 | -45.60 | 99 | 13.10 | 9.80 | 14 | 14 |
| 2025: Q3 | 0.11 | 105.00 | 114 | 35.30 | 14.70 | 29 | 25 |
| 2025: Q4 | 0.10 | 103.30 | 118 | 27.10 | 12.90 | 25 | 25 |
| 2026: Q1 | -0.07 | -255.90 | 59 | -33.10 | -18.40 | 2 | 1 |
| 2026: Q2 | -0.10 | -266.70 | 64 | -34.70 | -23.00 | -10 | -10 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
About the Company
MiMedx Group, Inc. entwickelt und vertreibt Plazentagewebe-Allografts für verschiedene Bereiche des Gesundheitswesens.
| Employees | 808 |
|---|---|
| Headquarters | Marietta, GA |
| Website | mimedx.com |
| IPO Date | 22. Aug 2007 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Joseph H. Capper | CEO & Director | 1964 |
| Douglas C. Rice CPA | Chief Financial Officer | 1966 |
| William F. Hulse IV | General Counsel & Chief Administrative Officer | 1974 |
| Kimberly Maersk-Moller | Chief Commercial Officer | 1967 |
| John Harper Ph.D. | SVP of R&D & Medical Affairs and Chief Scientific Officer | – |
| Matthew M. Notarianni | Head of Investor Relations | – |
| Mark P. Graves | Senior VP & Chief Compliance Officer | 1966 |
| Hilary Dixon | Vice President of Investor Relations & Corporate Strategic Communications | – |
| Eric A. Smith | Senior VP of Marketing & International | 1972 |
| Tracy Chastain | Chief Human Resources Officer | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.